Pubdate: Wed, 30 Nov 2011
Source: Los Angeles Times (CA)
Copyright: 2011 Los Angeles Times
Contact:  http://www.latimes.com/
Details: http://www.mapinc.org/media/248
Author: Melissa Healy
Bookmark: http://www.mapinc.org/hallucinogens.htm (Hallucinogens)
Bookmark: 
http://mapinc.org/topic/Multidisciplinary+Association+for+Psychedelic+Studies

TURN ON, TUNE IN AND GET BETTER?

Hallucinogens and other street drugs are increasingly being studied 
for legitimate therapeutic uses, such as helping patients deal with 
post-traumatic stress disorder, addiction, chronic pain, depression 
and even terminal illness.

Janeen Delany describes herself as an "old hippie" who's smoked 
plenty of marijuana. But she never really dabbled in hallucinogens - 
until two years ago, at the age of 59.

A diagnosis of incurable leukemia had knocked the optimism out of the 
retired plant nurserywoman living in Phoenix. So she signed up for a 
clinical trial to test whether psilocybin - the active ingredient in 
"magic mushrooms" - could help with depression or anxiety following a 
grim diagnosis.

Delaney swallowed a blue capsule of psilocybin in a cozy office at 
Johns Hopkins University in Baltimore. She donned a blindfold, a 
blood pressure cuff and a headset playing classical music. With two 
researchers at her side, she embarked on a six-hour journey into 
altered consciousness that she calls "the single most life-changing 
experience I've ever had."

What a long, strange trip it's been. In the 1960s and '70s, a 
rebellious generation embraced hallucinogens and a wide array of 
street drugs to "turn on, tune in and drop out." Almost half a 
century later, magic mushrooms, LSD, Ecstasy and ketamine are being 
studied for legitimate therapeutic uses. Scientists believe these 
agents have the potential to help patients with post-traumatic stress 
disorder, drug or alcohol addiction, unremitting pain or depression 
and the existential anxiety of terminal illness.

"Scientifically, these compounds are way too important not to study," 
said Johns Hopkins psychopharmacologist Roland Griffiths, who 
conducted the psilocybin trial.

In their next incarnation, these drugs may help the psychologically 
wounded tune in to their darkest feelings and memories and turn 
therapy sessions into heightened opportunities to learn and heal.

"We're trying to break a social mind-set saying these are strictly 
drugs of abuse," said Rick Doblin, a public policy expert who founded 
the Multidisciplinary Assn. for Psychedelic Studies in 1986 to 
encourage research on therapeutic uses for medical marijuana and 
hallucinogens. "It's not the drug but how the drug is used that matters."

Regulators and medical researchers remain wary. But among at least 
some experts at the National Institutes of Health and the Food and 
Drug Administration, the shift in attitude "has been dramatic," Doblin said.

Researchers explored the usefulness of hallucinogenic agents as an 
adjunct to psychotherapy in the 1950s and '60s. But allegations that 
hallucinogens were used in government-funded "mind control" efforts, 
freewheeling experimentation by proponents like Dr. Timothy Leary, 
and the drugs' appeal to a generation in revolt quashed legitimate 
research for decades.

The thaw has been slow in coming. In 2008, Griffiths co-wrote a 
report in the Journal of Psychopharmacology comparing psilocybin with 
a placebo for people dealing with incurable diseases. Psilocybin 
resulted in "mystical experiences having substantial and sustained 
personal meaning and spiritual significance," according to the study, 
the first since 1972 to explore a hallucinogen's therapeutic value.

In January, a team led by UCLA psychiatrist Charles Grob reported in 
Archives of General Psychiatry that psilocybin improved the mood of 
patients with "existential anxiety" related to advanced-stage cancer. 
The benefits lasted at least three months.

Janeen Delany is a typical case: The insights she gleaned during her 
encounter with psilocybin continue to shape her attitudes toward life 
and death.

Delany said her "trip" awakened a deep and reassuring sense of 
"knowing." She came to see the universe and everything in it as 
interconnected. As the music in her headphones reached a crescendo, 
she held her breath and realized it would OK - no, really easy - not 
to breathe anymore. She sensed there was nothing more she needed to 
know and therefore nothing she needed to fear about dying.

And that, paradoxically, has allowed her to live.

"When you take the veil of fear away from your life, you can see and 
experience everything in such a present way," she said. "I don't have 
to know what the future is. Every day is the day of days."

Fighting addiction

Such mystical insights are central in another potential use for 
psilocybin - as an addiction treatment. Griffiths is conducting a 
pilot study combining psilocybin with cognitive behavioral therapy to 
help smokers quit. Four people have completed the program, and so far 
none has returned to smoking, Griffiths says.

At the University of Arizona in Tucson, addiction specialist Dr. 
Michael P. Bogenschutz has proposed a clinical trial to test whether 
psilocybin can help ease alcohol dependence. If the NIH agrees to 
fund the study, it would be the first instance in decades of 
government financial support for a trial involving any drug of abuse.

Psilocybin's effect on the brain can be described, if not explained. 
It increases the activity of serotonin, a chemical that affects mood. 
Brain networks associated with emotions are highly active in the 
presence of psilocybin, as are structures involved in higher 
reasoning and judgment, MRI scans show.

Griffiths says that subjects routinely describe their psilocybin 
experience as one that "helps reorganize their thinking." For those 
facing death, that can bring new perspective on loved ones, on life 
and on what lies beyond; for those stymied by addiction, it can cut 
the addictive substance down to size. "Their enslavement to cigarette 
smoking will be almost funny," Griffiths said.

Psilocybin isn't the only drug on the cusp of a medical renaissance. 
Ketamine, best known as "Special K," has shown promise as a 
fast-acting antidepressant. It induces euphoria, hallucinations and 
"out of body" experiences when smoked or snorted. When administered 
intravenously at low doses, it can lift symptoms of deep depression 
in a matter of hours.

Ketamine's use in anesthesia has made it easier for researchers to 
study. They suspected its influence on a neurochemical called NMDA 
would make it a good antidepressant, since NMDA's activity is altered 
in people with depression.

In case reports, severely depressed patients who got ketamine in 
preparation for electroconvulsive shock therapy showed improvements 
in mood (even when the shock therapy failed), and several small 
clinical trials have demonstrated its fast-acting abilities. The 
findings indicate that for suicidal patients who can't afford to wait 
weeks or months for a standard antidepressant to take effect, 
ketamine could be a valuable rescue drug.

LSD may also be on the road to legitimacy. A 2006 study in Neurology 
surveyed people who used the drug to cope with persistent cluster 
headaches and found that it cleared them up and made them less 
frequent in most cases.

The results prompted Dr. John Halpern of Harvard Medical School's 
McLean Hospital to test a nonhallucinogenic LSD analog from the 
vaults of pharmaceutical giant Sandoz. At a research meeting in June, 
Halpern reported that 2-Bromo-LSD reduced the number of daily cluster 
headaches in six sufferers who participated in a pilot study.

Treating trauma

War has also created openings for the rehabilitation of some of these 
drugs. Ecstasy is a case in point.

The drug - whose chemical name is methylene dioxy methamphetamine, or 
MDMA - was patented in 1912 by Merck & Co. Its psychoactive 
properties prompted doctors to prescribe it for their patients; one 
pharmacologist called it "penicillin for the soul." But in 1988, the 
Drug Enforcement Agency declared MDMA a Schedule 1 controlled 
substance with high potential for abuse. Psychotherapists stopped 
prescribing it or continued to do so furtively.

On the street, Ecstasy has a reputation for dissolving anxiety and 
fear, suppressing social inhibition and enhancing one's willingness 
to trust others. PTSD sufferers avoid reminders of their pain or shut 
down at the prospect of facing it. A dose of Ecstasy appears to help 
these patients revisit their traumas and reflect on them without fear.

"It can connect people more with their emotions without them feeling 
they'll be overwhelmed by them," said psychiatrist Michael Mithoefer 
of Charleston, S.C., a clinical investigator for the 
Multidisciplinary Assn. for Psychedelic Studies.

Mithoefer has received FDA permission to test whether Ecstasy can 
help Iraq and Afghanistan veterans overcome their PTSD when used 
during psychotherapy sessions; six veterans have enrolled in the 
study. In an earlier clinical trial, Ecstasy helped 10 of 12 women 
recover from PTSD stemming from child sexual trauma. Only 2 out of 8 
women who took a placebo had similar results, Mithoefer reported last 
year in the Journal of Psychopharmacology.

Ecstasy's reputation for enhancing trust has clear roots in its 
biological effect. Using brain scans, Columbia University 
psychologist Gillinder Bedi found that subjects who took MDMA showed 
heightened activity in a brain region associated with processing 
rewards and depressed activity in the amygdala - a source of fear 
reactions. In animals, MDMA boosts the hormone oxytocin, which 
promotes trust, sociability and interpersonal attachment.

A drug can't be dismissed because of a dangerous reputation or 
colorful history, Bedi said, if trials demonstrate that it is safe 
and can benefit patients.

New life

Janeen Delany said her psilocybin experience had added life to her 
years - and perhaps years to her life.

Every three months, she gets her white blood cells checked. With her 
form of leukemia, those counts are expected to rise steadily as the 
disease progresses. But in June 2009, four months after her 
psilocybin session, they went down. Every three months since, they 
have retreated further, leading two of her three doctors to declare 
her in remission.

Delany said her psychological improvement may have helped reverse her 
fortunes. Her lead oncologist is skeptical, but her neurologist is 
not so quick to dismiss the link. One should never underestimate "the 
healing power of the psyche," he told her.

Whatever, Delany said. Remission is beside the point.

"The fear is gone. It's all about living," she said. "The big stuff? 
Sheeesh - it's handled."
- ---
MAP posted-by: Jay Bergstrom